NCT02079740 - Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

December 1, 2022

Study Completion Date

March 6, 2026

Conditions

Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo conventional CT or PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Navitoclax

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Trametinib

Given PO

Trial Locations (2)

Massachusetts General Hospital Cancer Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH